This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
PPAP
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict SKIP-FOR-NOW HIGH
PPAP is the first CAE compound and a historical-mechanistic milestone, but its successor BPAP is ~130× more potent in vivo (full antagonism of tetrabenazine depression at 0.05 mg/kg vs PPAP's 2.5 mg/kg), enhances serotonin in addition to catecholamines, and is the actively-researched compound in this family. For this-archetype the rational move at this CAE-class slot is BPAP if the watch-list moves to active, OR low-dose selegiline (which has 40+ years of human data and Rx access) if MAO-B inhibition is also wanted. PPAP has zero unique value vs BPAP and zero human RCTs. Would re-evaluate ONLY if BPAP sourcing collapses AND a human PPAP trial emerges — not expected.
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
★20-30, brain-priority, high cognitive workload (this-archetype) | SKIP-FOR-NOW | PPAP has zero unique value vs the alternatives. If the goal is MAO-B-preserving DA tone, low-dose selegiline (1-2.5 mg) has 40+ years of human safety data and an Rx path. If the goal is pure CAE without MAO inhibition, BPAP is ~130× more potent in vivo, adds serotonin enhancement, and is the actively-researched compound. PPAP is historical only. |
30-50, executive maintenance | SKIP-FOR-NOW | Same logic. Selegiline or BPAP fill the slot more cleanly. |
50+, mild cognitive decline | SKIP-FOR-NOW | Selegiline has the actual evidence base in this demographic. PPAP would be experimentation without evidence support. |
Anxiety-prone | SKIP | NE-elevating CAE compound with reported anxiety at higher doses + zero formal safety data is not the right fit. |
High athletic load, tested status | SKIP | PPAP is structurally a phenethylamine derivative — could trigger urine amphetamine screen false positives. Not WADA-listed by name but the IOC's "and related substances" catch-all clause likely includes PPAP. Tested athletes should not touch this. |
Sleep-disordered | SKIP | Adding any DA/NE enhancer with poor characterization is the wrong move when sleep is the limiting factor. |
Recovery-focused (post-injury, post-illness) | SKIP | No mechanism here is recovery-specific. BPC-157, GHK-Cu, methylene blue have stronger cases. |
Strength/anabolic-focused | SKIP | Not in the anabolic pathway at all. Verdict across all archetypes: SKIP-FOR-NOW or WATCH-LIST at most. No archetype gets a STRONG-CANDIDATE or even OPTIONAL-ADD verdict for PPAP because BPAP exists and dominates on every dimension that matters. |
- ★20-30, brain-priority, high cognitive workload (this-archetype)SKIP-FOR-NOW
PPAP has zero unique value vs the alternatives. If the goal is MAO-B-preserving DA tone, low-dose selegiline (1-2.5 mg) has 40+ years of human safety data and an Rx path. If the goal is pure CAE without MAO inhibition, BPAP is ~130× more potent in vivo, adds serotonin enhancement, and is the actively-researched compound. PPAP is historical only.
- 30-50, executive maintenanceSKIP-FOR-NOW
Same logic. Selegiline or BPAP fill the slot more cleanly.
- 50+, mild cognitive declineSKIP-FOR-NOW
Selegiline has the actual evidence base in this demographic. PPAP would be experimentation without evidence support.
- Anxiety-proneSKIP
NE-elevating CAE compound with reported anxiety at higher doses + zero formal safety data is not the right fit.
- High athletic load, tested statusSKIP
PPAP is structurally a phenethylamine derivative — could trigger urine amphetamine screen false positives. Not WADA-listed by name but the IOC's "and related substances" catch-all clause likely includes PPAP. Tested athletes should not touch this.
- Sleep-disorderedSKIP
Adding any DA/NE enhancer with poor characterization is the wrong move when sleep is the limiting factor.
- Recovery-focused (post-injury, post-illness)SKIP
No mechanism here is recovery-specific. BPC-157, GHK-Cu, methylene blue have stronger cases.
- Strength/anabolic-focusedSKIP
Not in the anabolic pathway at all. Verdict across all archetypes: SKIP-FOR-NOW or WATCH-LIST at most. No archetype gets a STRONG-CANDIDATE or even OPTIONAL-ADD verdict for PPAP because BPAP exists and dominates on every dimension that matters.
▸ Subjective experience (deep)
Per the very limited research-chem user reports:
- Onset: 30-60 min sublingual / oral
- Peak: ~2-3 hours
- Duration: ~5 hours total
- Profile: "Amphetamine-like focus without tunnel vision," motivation lift, mental clarity, mild physical activation. Not euphoric. Less intense than amphetamine, less wired than methylphenidate. Some users describe it as "selegiline-like but with more drive."
- Variability: Reports range from "noticeable" to "barely perceptible" — typical for low-potency CAE compounds where individual baseline DA tone strongly modulates response.
- Honesty caveat: The user-experience corpus is so thin that subjective characterization is closer to vibes than data. Anyone considering PPAP would essentially be doing n=1 experimentation.
▸ Tolerance + cycling deep dive
- Tolerance buildup: Unknown in humans. Animal data (acute dosing studies) doesn't address chronic use. Mechanism prediction would be low tolerance (impulse-coupled release doesn't drive the supraphysiologic flooding that downregulates D2). But this is not validated.
- Recommended cycle: No data. If using, default to weekday-on / weekend-off until data exists.
- Reset protocol: Unknown. Days of washout, presumably.
▸ Stacking deep dive
Synergistic with (theoretical, no human evidence)
- modafinil: Different mechanisms — modafinil raises orexin/histamine + weak DAT inhibition; PPAP enhances impulse-coupled DA/NE release + (per 2025 data) DAT inhibition. Limited research-chem reports describe additive focus. Caveat: the DAT-overlap means the "different mechanisms" framing is partly broken — both compounds touch DAT.
- bromantane: Bromantane upregulates DA synthesis (substrate-side); PPAP enhances release per impulse (output-side). Mechanistically clean — synthesis + release work on different stages. No human stack data.
Avoid stacking with
- selegiline: NEVER COMBINE. Both target the CAE/TAAR1 mechanism. Adding PPAP to selegiline (especially at any tier above 5 mg oral selegiline) produces overlapping CAE drive with no cleanly characterized human pharmacokinetic data on the combination. Pick one. If MAO-B inhibition is desired, use selegiline alone. If pure CAE without MAO inhibition is desired, use BPAP alone (not PPAP).
- bpap: Same family, redundant. Pick one.
- MAOIs (phenelzine, tranylcypromine, rasagiline, linezolid, methylene blue): Hypertensive crisis + serotonin syndrome risk. PPAP itself doesn't inhibit MAO, but raising synaptic catecholamines in the presence of MAO-A inhibition is the classic pressor-amine setup.
- SSRIs / SNRIs: Theoretical serotonin syndrome risk via the catecholamine-serotonin crosstalk pathways. PPAP itself is catecholamine-selective (not serotonergic) so this risk is lower than with BPAP, but it is still nonzero.
- Amphetamines / methylphenidate / cocaine: Additive DAT load (per 2025 reuptake data) + additive sympathomimetic activation. Avoid.
- Tramadol, meperidine, methadone, DXM: Same serotonergic-opioid cautions as for any monoamine-active drug.
Neutral / safe co-administration (theoretical)
- Caffeine: no known interaction.
- Magnesium / D3 / K2 / DHA / NAC / citicoline: neutral.
- Russian peptides (Semax, Selank, Adamax): no documented interaction.
▸ Drug interactions deep dive
PPAP has no validated CYP-enzyme interaction profile published. Its parent compound class (phenethylamines) typically interact with CYP2D6 / CYP2B6 — but PPAP-specific CYP characterization is absent. Absence of data ≠ absence of interaction; treat with caution.
▸ Pharmacogenomics
None published for PPAP specifically. By inference from the deprenyl/CAE family:
- TAAR1 polymorphisms could plausibly modulate response (TAAR1 is the proposed mechanism target).
- DRD2/ANKK1 Taq1A: D2 receptor density baseline. Plausibly affects response to any DA-enhancing compound including PPAP.
- COMT Val158Met: Met/Met (high PFC DA tone) might respond less / get more anxiety; Val/Val (low PFC DA tone) might benefit more.
For the user's 23andMe results (June 2026): these SNPs are checked anyway for selegiline/bromantane/modafinil response — the same panel covers PPAP-relevant inference.
▸ Sourcing deep dive
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| Research-chem powder (HCl) | Venogen | $39.95/g | Medium-high (claims 99%, 3rd-party HPLC, COA available); often out of stock | Worldwide shipping; explicitly "not for human use" |
| Research-chem powder | Kimera Chems | $77-92/g | Medium (claims ≥98% HPLC, COA available as image on product page) | Stocked; powder or DMSO/PEG400 liquid (20 mg/mL) |
| Research-chem powder | Umbrella Labs | Variable | Medium | Has stocked PPAP intermittently |
| Research-chem powder | Euro-Nootropics | Variable | Low-medium | Less established vendor |
| Research-chem powder | GlobalChemSolutions | Variable | Low | Less established |
| Bulk Alibaba | Various Chinese suppliers | ~$10/g at 50g+ scale | Low (no COA, no quality assurance) | Historical group-buy path; not recommended |
| Newmind | Discontinued / unreliable | — | Low | User reports of months-long stockouts circa 2018-2020 |
Cost reality: PPAP at 30 mg/dose × 30 days = 0.9 g/month. At Venogen pricing ($39.95/g) that's ~$36/month for ingredient. At Kimera ($77-92/g) that's ~$70-83/month. For comparison, BPAP at 1 mg/dose × 30 days = 0.03 g/month — at typical BPAP pricing of $40-60 per ~30 mg, that's ~$40-60/month for the ingredient. The two compounds end up at roughly similar monthly cost despite the 30-50× dose difference, because BPAP is priced higher per gram.
For the user: do not source. This is the kind of compound to recognize, understand its place in pharmacology history, and skip.
▸ Biomarkers to track (deep)
If somehow used (against this verdict):
- Baseline: Resting BP, orthostatic BP, HR, mood self-report, sleep onset latency, liver panel.
- During use: BP + HR weekly first month; sleep metrics; mood/drive self-report; watch for any hypertensive symptoms.
- Post-cycle: BP + mood return to baseline within 1-2 weeks expected (no human data to confirm).
▸ Controversies / open debates Live debate
"Pure CAE" vs "DAT inhibitor" — the 2025 mechanism revision
Knoll's 1990s-2000s framing of PPAP was "pure impulse-coupled CAE, no reuptake inhibition, no direct release." The 2025 in-vitro reuptake data (PPAP DAT IC50 57.5 nM, more potent than amphetamine at DAT) directly contradicts the no-reuptake claim. My read: Knoll's assays (synaptosomal release in tissue prep) may have systematically missed reuptake inhibition. Or the mechanism is genuinely dual — CAE activity gated by impulse firing PLUS reuptake inhibition raising tonic levels. Either way, the original "pure physiological-gated DA enhancer" branding is now somewhat overstated. This matters because the "no abuse liability, no neurotoxicity, no tolerance" predictions all depend on the impulse-coupled-only story. If PPAP is also a potent DAT inhibitor, those predictions need re-derivation.
Why didn't PPAP reach human trials when Knoll wanted it to?
Knoll's group attempted clinical development. It didn't happen. The likely explanation is some combination of: (1) amphetamine derivative status creating regulatory friction in the post-MDMA crackdown era of the 1990s, (2) limited commercial interest in a "weaker amphetamine" compared to the booming SSRI-class antidepressant market, (3) Knoll himself moving on to BPAP almost immediately upon synthesis, leaving PPAP a dead-letter compound. There is no documented safety reason for the failure to reach trials.
BPAP supersession — is anything lost?
PPAP's distinguishing feature vs BPAP is catecholamine selectivity (no serotonin enhancement). For someone who specifically wants DA + NE enhancement without any serotonin elevation — e.g., someone on an SSRI who wants additive cognition without serotonin syndrome risk — PPAP would theoretically be safer than BPAP. Caveat: this theoretical edge has never been tested clinically. It's a hypothesis, not a documented advantage.
The TAAR1-agonism family hypothesis
2020s neurochem reviews group PPAP, BPAP, and selegiline as TAAR1 agonists (EPPTB-reversal evidence is strongest for BPAP). If true, the entire CAE family shares a single G-protein-coupled-receptor mechanism. This would make PPAP/BPAP/selegiline functionally equivalent at sufficient receptor occupancy — the differences (potency, selectivity, MAO inhibition vs not) would be secondary properties. PPAP-specific EPPTB-reversal data is thinner than for BPAP, leaving this an open question.
▸ Verdict change log
- 2026-05-05 — Initial verdict: SKIP-FOR-NOW HIGH confidence. PPAP is a historical compound superseded by BPAP on every relevant dimension. For this-archetype, the CAE slot is filled by selegiline (Rx, evidence, daily-safe) or BPAP (research-chem, ~130× more potent than PPAP, also adds serotonin enhancement). PPAP would only be relevant if BPAP sourcing collapsed AND a serotonin-avoidance use case emerged — neither expected.
▸ Open questions / gaps Open
- Why no human trial in 30+ years? The historical record is sparse. Was a Phase 1 ever attempted? Why did it fail? Knowing this would clarify whether PPAP has an undisclosed safety problem or just lost the corporate-development race to BPAP.
- Pure-CAE vs DAT-inhibitor mechanism dominance. If PPAP is mostly a DAT inhibitor with secondary CAE, its safety/abuse profile predictions need revision. A cleanly designed in-vivo experiment (e.g., DAT-knockout mice + PPAP behavior) would settle this. None published as of 2026-05.
- PPAP-specific EPPTB-reversal experiments. Confirms or refutes TAAR1 as the PPAP mechanism, independently of BPAP data. None published.
- Long-term chronic dosing toxicology in primates. Never done. Anyone using PPAP chronically is functionally testing this in n=1.
- Stereoselectivity of pharmacology. (-)-PPAP is the active enantiomer per Knoll's work, but most research-chem product is sold as racemic or unspecified-enantiomer "PPAP HCl." Does (+)-PPAP have its own pharmacology? Unknown.
References
Knoll et al. 1992 — The pharmacology of 1-phenyl-2-propylamino-pentane (PPAP) (Arch Int Pharmacodyn Ther) (PubMed 1356324)
detailed pharmacological characterization
View StudyKnoll et al. 1996 — (-)Deprenyl and (-)PPAP act primarily as potent stimulants of action potential-transmitter release coupling (Life Sciences) (PubMed 8602114)
mechanism-defining paper, MAO-independence
View StudyKnoll 1999 — (-)BPAP, a selective enhancer of impulse propagation mediated release (Br J Pharmacol) (PMC1571822)
BPAP introduction with PPAP comparison; gives the dose-ratio data establishing BPAP's ~130× potency advantage
View StudyEnhancer Regulation of Dopaminergic Neurochemical Transmission in the Striatum (MDPI IJMS 23:8543, 2022)
modern review of CAE family mechanism
View StudyTAAR1 + BPAP mechanism (Neurochem Res 2025)
recent CAE/TAAR1 mechanism work, places PPAP in the family
View StudyKnoll et al. 1990 — MK-306: A deprenyl-derived new spectrum psychostimulant (Eur J Pharmacol 183:454-455)
original report
View SourcePhenylpropylaminopentane (Wikipedia)
comprehensive overview, includes the 2025 reuptake-inhibition update with DAT/NET/SERT IC50 values
View SourceBenzofuranylpropylaminopentane (Wikipedia)
BPAP context including the 130× potency ratio
View SourceKnoll — The Discovery of the Enhancer Regulation in the Catecholaminergic and Serotonergic Brain System (INHN historical e-book)
Knoll's own retrospective of the deprenyl → PPAP → BPAP arc
View SourceVenogen — PPAP Hydrochloride product page
$39.95/g, claims 99% HPLC purity, COA via batch lookup, often out of stock
View SourceKimera Chems — PPAP product page
$77-92/g, claims ≥98% HPLC, COA on product page
View SourceUmbrella Labs — The Role of PPAP (April 2024 article)
vendor-published overview, marketing-flavored
View SourceLongecity PPAP group buy thread
user reports 30 mg sublingual dosing, ~5 hr duration, "amphetamine focus without tunnel vision"
View SourceBluelight BPAP thread (BPAP-focused but discusses family)
context for the family
View SourceFirst Experience with PPAP HCl (Tumblr archive of Reddit reports)
user trip report
View SourceHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.